Trenchant Biosystems

Trenchant Biosystems develops the AutoCell platform for automating patient-specific cell and gene therapy (CGT) manufacturing, enabling scalable production in ISO class 7 environments at the place of care. The technology uses microbubble separation to achieve 7-fold higher gene-modified cell yields, reduce costs by up to 80%, and shorten vein-to-vein timelines from six weeks to 2.5 days. Partnerships with Invetech, UMass Chan Medical School, and Caring Cross advance the platform toward fully automated commercial products for applications like sickle cell disease therapies.

Industry categories: CDMO & Manufacturing, Lab Equipment & Instruments. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.